Effectiveness of Sustained Release Calcium Butyrate on the microbiome and clinical burden in osteoarthritis of the hand: A proof-of-concept placebo-controlled randomized trial
Osteoarthritis and Cartilage · 2026
DOI: 10.1016/j.joca.2026.01.630 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Osteoarthritis and Cartilage, 2026. Verfasst von M Hartog und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research, Sint Maartenskliniek, Nijmegen, the Netherlands; Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands;…. Hauptthemen laut MEDLINE: Osteoarthritis, Gastrointestinal Microbiome, Butyric Acid. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
OBJECTIVE: This study primarily assessed effects of Sustained Release Calcium Butyrate (SRCaBu) on gut microbiome composition and function in hand OA patients. Secondary objectives included its impact on hand pain and function, markers of intestinal permeability, systemic inflammation, and safety. METHOD: A participants, researchers, and pharmacy assistants blinded, randomized, placebo-controlled proof-of-concept trial compared 600 mg daily dose SRCaBu with placebo over 4-5 weeks. The primary domain was microbiome composition and function, assessed via fecal 16S rRNA gene- and metagenome sequencing, and short-chain fatty acid analysis. Secondary outcomes included parameters for intestinal barrier function, clinical outcomes and adverse events. Primary analyses followed the per-protocol principle. RESULTS: 35 participants (mean age 62.5±6.9 years, 82% female) were randomized to SRCaBu (n=18) or placebo (n=17). Two SRCaBu participants discontinued treatment for pre-existing liver impairment and need for pain medication. SRCaBu tended to reduce the relative abundance of Streptococcus (regression coefficient:-0.67, 95%CI:-1.46,0.13) and Faecalibacterium -0.38(-0.83,0.07), increase fecal acetate (median between-group difference: 9.5, [IQR]: [-3.5,22.5]), and was inversely associated with microbial LPS biosynthesis- and virulence genes. SRCaBu increased toxin-related genes, primarily from beneficial Blautia species, without association to pathogenicity. SRCaBu did not significantly affect biomarkers of intestinal permeability, inflammation, or clinical outcomes. Adverse events were mild and comparable between groups. CONCLUSION: Our study yielded indicative findings that SRCaBu supports microbiome health in patient with hand OA by improving compositional and functional characteristics of the microbiome. Although the treatment was well tolerated, effects on serum markers for intestinal barrier function and systemic inflammation, and clinical symptoms remained unclear. TRIAL REGISTER: 2020-001071-33 / NL73382.091.21.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research, Sint Maartenskliniek, Nijmegen, the Netherlands; Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands; Department of Rheumatology, Radboudumc, Nijmegen, the Netherlands. El…
- Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands; Tiofarma B.V., Oud-Beijerland, the Netherlands. Electronic address: sandra_korsten@hotmail.com.
- Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands; Department of Rheumatology, Radboudumc, Nijmegen, the Netherlands. Electronic address: C.Popa@maartenskliniek.nl.
- Department of Primary and Community Care, Radboud University Medical Center, Research Institute for Medical Innovation, Nijmegen, the Netherlands. Electronic address: Tim.Pelle@radboudumc.nl.
- Laboratory of Microbiology, Wageningen University & Research, Wageningen, the Netherlands; UNLOCK, Wageningen University & Research, Delft University of Technology, Wageningen, Delft, the Netherlands. Electronic address…
- Department of Research, Sint Maartenskliniek, Nijmegen, the Netherlands; Department of Pharmacy, Radboudumc, Nijmegen, the Netherlands. Electronic address: B.vandenbemt@maartenskliniek.nl.
Zitieren
APA
Hartog, M., Korsten, S. G. P. J., Popa, C. D., Pelle, T., Gavriilidou, A., van den Bemt, B. J. F., Willemsen, L. E. M., Koenders, M. I., Vermeiden, J. P. W., Smidt, H., & van den Ende, C. H. M. (2026). Effectiveness of Sustained Release Calcium Butyrate on the microbiome and clinical burden in osteoarthritis of the hand: A proof-of-concept placebo-controlled randomized trial. Osteoarthritis and Cartilage. https://doi.org/10.1016/j.joca.2026.01.630
Vancouver
Hartog M, Korsten SGPJ, Popa CD, Pelle T, Gavriilidou A, van den Bemt BJF, et al. Effectiveness of Sustained Release Calcium Butyrate on the microbiome and clinical burden in osteoarthritis of the hand: A proof-of-concept placebo-controlled randomized trial. Osteoarthritis and Cartilage. 2026. doi:10.1016/j.joca.2026.01.630
BibTeX
@article{Hartog2026,
author = {Hartog, M and Korsten, S G P J and Popa, C D and Pelle, T and Gavriilidou, A and van den Bemt, B J F and Willemsen, L E M and Koenders, M I and Vermeiden, J P W and Smidt, H and van den Ende, C H M},
title = {Effectiveness of Sustained Release Calcium Butyrate on the microbiome and clinical burden in osteoarthritis of the hand: A proof-of-concept placebo-controlled randomized trial},
journal = {Osteoarthritis and Cartilage},
year = {2026},
doi = {10.1016/j.joca.2026.01.630}
}
EUVIMED